within Pharmacolibrary.Drugs.ATC.C;

model C04AX32
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 6.944444444444445e-06,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,
    adminCount     = 1,
    Vd             = 0.03,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.027,
    k12             = 18,
    k21             = 18
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>ATC code:</td><td>C04AX32</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Fasudil is a selective Rho-kinase inhibitor primarily used in the treatment of cerebral vasospasm following subarachnoid hemorrhage and has been investigated for use in pulmonary hypertension and other vascular conditions. It is approved in Japan but not widely approved elsewhere.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for adult healthy male volunteers after intravenous administration.</p><h4>References</h4><ol><li><p>Wolff, AW, et al., &amp; Lingor, P (2024). SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants. <i>CNS drugs</i> 38(4) 291â€“302. DOI:<a href=\"https://doi.org/10.1007/s40263-024-01070-7\">10.1007/s40263-024-01070-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38416402/\">https://pubmed.ncbi.nlm.nih.gov/38416402</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>"
  ));
end C04AX32;
